The Protocol Framework
To address ME/CFS and halt the intracellular cortisol starvation driven by MR overactivity under the rs5522 framework, the model proposes a precise, tiered approach:
1. The Core Focus (Primary Mechanism)
Targeting the Hyperactive MR: Utilizing a low-dose mineralocorticoid receptor antagonist, such as 25mg spironolactone (or eplerenone for male patients). This is the foundation designed to physically block the baseline "cortisol steal" at the receptor level and restore natural hormone distribution to the remaining GR receptors.
2. Supportive Options (Secondary / Case-by-Case)
Supporting the Starved GR (Optional): Evaluating the addition of low-dose hydrocortisone—strictly for the specific subset of patients who present with objective clinical symptoms of adrenal insufficiency. This is an optional tool to help restore cellular energy only if the baseline adrenal output is genuinely depleted.
Deploying Anti-Inflammatory Stabilizers (Optional): Integrating low-dose naltrexone (LDN) or a GLP-1 receptor agonist as secondary, supportive agents. These work further down the line to help control downstream vascular inflammation and allow the mitochondrial engines to recover while the primary MR blockade does its work.
Clinician reference sheets are available here.
Frequently Asked Questions
Question: How can a common variant like rs5522 cause ME/CFS symptoms?
Answer: : The short answer is that rs5522 isn’t a guaranteed disease sentence; it’s a baseline vulnerability. It means you inherit a system that permanently runs on high MR overactivity and low GR activation. Cortisol activates the glucocorticoid receptor (GR) and is absolutely essential for standard cellular energy production—this is basic, well-established biology. However, people who develop ME/CFS likely carry other genetic variants that code for an overabundance of MR receptors, alongside background genes that directly impair fully functioning GR and ATP production. As a result, your core energy pipeline is compromised from the start, leaving you completely exposed if a severe infection or major trauma hits the system.
Think of it this way: if rs5522 turns your receptor into a cortisol-stealing vacuum, your secondary genes act like a power booster. A major study showed that when these genes team up, they add a whopping 40% more power to the vacuum, locking the body into perpetual chronic exhaustion.
As a result of this compounding genetic pile-up, your core cellular energy pipeline is deeply compromised from the start, leaving you completely exposed if a severe infection or major trauma hits the system.
If that vulnerable system gets hit by a severe infection or major trauma it will collapse. People with this variant are often able to function until a viral infection (EBV, CMV, SARS-CoV-2) kicks them into illness. This is not necessarily because the virus stays in their system, but because research shows the virus itself damages the glucocorticoid receptor inside the cell, often altering and sometimes ejecting it from the cell nucleus. When these viruses deform the GR gates in a patient who already carries the baseline rs5522 overactive mineralocorticoid receptor, the two factors compound. The receptor vacuum hoards the available cortisol fuel at the gate, while the virus damages the remaining machinery. This combination completely severs the body’s master anti-inflammatory brake and energy-creating pathways.
Look at Long COVID: the virus doesn't need to stay in your body to keep you sick. It just acts as an initial sledgehammer that directly alters your glucocorticoid receptors, pushing an already strained system right over the precipice into permanent illness.
Most importantly, a receptor does not have a fixed setting. Molecular research indicates that how a receptor responds to a hormone depends entirely on the unique cellular environment it sits in. Because these receptors are everywhere, this local variation is exactly why so many completely different systems—from your immune defense to your core cellular energy—can be impaired at the same time, and why the ultimate manifestation of this variant can differ so wildly from person to person.
Because these receptors are present in every cell of the body, the specific disease you develop may depend on how the variant behaves within that specific tissue environment.
The people carrying this variant who don’t have ME/CFS are still experiencing functional GR starvation. Their tissue environment and background genes might keep them highly compensated for decades, but inflammation accumulates silently beneath the surface long before clinical symptoms appear. Even individuals who go their whole lives with seemingly normal energy levels may simply be burning through their structural defenses, until their brain eventually succumbs to neuroinflammatory illnesses like Alzheimer's or Parkinson's.
When it comes to recovery from ME/CFS, blocking these overactive MR receptors with targeted therapy can fix the problem at the source.
Question: Do I need to get genetic testing before trying a low dose of an MR antagonist (such as spironolactone, eplerenone, or finerenone)?
Answer: No, you do not absolutely require genetic testing before initiating a trial. While testing can provide valuable confirmation, a clinical trial of a low-dose mineralocorticoid receptor (MR) antagonist is often a practical first step under proper medical supervision.
The rs5522 genetic variant acts as an intracellular driver for a wide spectrum of presentation profiles. If you struggle with chronic fatigue, widespread pain, or fibromyalgia your clinician may consider a low-dose therapeutic trial based on your symptoms. These medications carry an extensive, well-established multi-decade safety profile and are routinely prescribed worldwide for benign dermatological conditions like acne.
Furthermore, population genomics show that rs5522 is exceptionally common in the general population. Depending on your specific ancestral background, the carrier frequency for this variant is remarkably high—meaning statistically, it is highly probable chronic symptoms are interacting with an underlying rs5522 baseline.
Because a low-dose trial (such as 12.5 mg to 25 mg of Spironolactone) is safe, accessible, and easily monitored, clinicians may opt to evaluate a patient's real-world clinical response directly, rather than waiting for genetic sequencing results.
Question: Aren't these just regular water pills or diuretics?
Answer: No. Calling these medications 'water pills' is a common misnomer. Standard water pills act as simple diuretics, forcing the kidneys to dump water directly from the bloodstream. In contrast, these belong to a completely different class of medication known as mineralocorticoid receptor (MR) antagonists.
To understand how they work, think of the receptors on your cells like locks, and your body's hormones like keys. With this genetic condition, your locks are "greedy.” They pull keys in too fast and refuse to let them go, keeping the switch permanently jammed in the "on" position. This constant overactivity (stuck in “on”) is what drives your chronic disease symptoms.
This medicine does not stop your body from making keys. In fact, doctors often call these medicines 'aldosterone blockers,' but that is a mechanistic misstatement because it is actually blocking the mineralocorticoid receptor (MR) itself. In the rs5522 framework, the partial blockade stops the MR receptor from vacuuming up too much cortisol and lets it be used by the glucocorticoid receptors (GR). Instead of changing your hormone production, the medicine acts like a dummy key that is specifically shaped to slide into that greedy lock first. It plugs the hole and stays there. Because the greedy lock is blocked, the overactive switch finally calms down and your body gets relief without ever changing your actual hormone levels.
While clinicians might worry that blocking the MR will drop blood pressure in a patient with orthostatic intolerance, they are forgetting a basic principle of physiology: blood vessels need cortisol to hold pressure. Without cortisol actively binding to the GR pathways to maintain arterial tone, blood vessels remain completely relaxed and unable to constrict.
This medication acts strictly as a cellular stabilizer at low doses (12.5-25mg) and does not cause the aggressive fluid drainage seen at large doses needed in heart failure. Once the low-dose blocks the MR receptor, it frees up natural cortisol to finally bind to the GR, allowing the relaxed blood vessels to properly constrict. By restoring that missing vascular tone, the low dose actually helps raise and stabilize blood pressure safely back to normal.
This low-dose approach is backed by decades of safety data from dermatology, where women are routinely treated for acne or cosmetic hair loss without experiencing low blood pressure —even at doses 2 to 4 times higher than what is recommended in this protocol. Because the molecule anchors into the local tissue to calm down hyperactive receptors rather than forcing a plumbing flush, it protects cells without triggering the harsh dehydration or systemic volume depletion associated with standard water pills.
We often think a pill only does one job, but changing the dose can completely change the biological pathway a drug activates inside the body. For example, at high doses, Naltrexone is a heavy-hitting addiction medication. But at ultra-low doses (LDN), it acts as a molecular shield, calming over-reactive nerve pathways and turning down chronic systemic inflammation. This same blueprint applies to low dose MR Antagonists. At low doses, the drug functions as a molecular shield blocking the MR from vacuuming up the cortisol the body actually needs to create baseline energy.
Question: Why do my standard blood, urine, and saliva cortisol tests always come back normal if I am completely non-functional?
Answer: If you are living with ME/CFS, Long COVID, or unexplained fatigue, you know the absolute hell of being completely non-functional while standard blood, urine, and saliva tests tell you there is nothing wrong with you.
This exact receptor bottleneck is why millions diagnosed with adrenal insufficiency are still completely unable to function fully even when taking daily prescription cortisol. Their endocrinologists are entirely blind to tissue-level starvation; they have no idea that the cortisol is simply being swallowed up out the back door before it can ever reach the tissues to control pain and create energy.
A massive laboratory breakthrough published in June 2026 in Biochemical and Biophysical Research Communications (Katsu, et al., 2026) finally explains why our tests look normal while our bodies are actively dying for energy and screaming in pain. It all comes down to a single genetic receptor variant called rs5522 and a biological bottleneck known as the "cortisol steal."
Cortisol is a highly promiscuous ligand. Millions of years ago, the Mineralocorticoid Receptor (MR) and the Glucocorticoid Receptor (GR) duplicated from the exact same ancestral receptor. Because of this evolutionary baseline, cortisol binds to both, but the MR holds a structurally dominant, 10-fold higher binding affinity for it.
When you carry the overactive rs5522 variant, the MR turns into a runaway vacuum. It preferentially captures and locks up the baseline cortisol pool. This leaves the lower-affinity GR completely starved of the vital fuel our cells require for baseline energy production, pain management, and anti-inflammation. Without GR activation, the cells trigger a protective mitochondrial and metabolic shutdown, forcing the nervous system to flood the body with adrenaline just to keep us upright (which is why you may feel permanently "wired and tired").
Because this bottleneck happens inside the cell receptors at the tissue level, circulating hormone counts miss the mark completely:
Your cortisol labs may be low and the tissues are starved.
Your cortisol labs may be normal, but the tissues are starved.
Your cortisol labs may occasionally test high, because the brain triggers an emergency override in response to systemic inflammatory distress signals, forcing the HPA axis to pump out more hormone even though the local tissue receptors remain completely starved. However, the system cannot sustain this state of chronic emergency overdrive indefinitely, and the HPA axis will eventually crash, leaving the body unable to produce enough hormone to combat the ongoing tissue starvation.
Medical testing is currently trapped in a massive conceptual error. To put it in perspective, endocrinologists are repeatedly checking the plumbing of the fuel tank while being unaware of the biophysics of the cellular receptors. By obsessing over circulating hormone levels in the blood, they merely confirm that the tank is full. They continue to blame the driver for a stalled vehicle, entirely unaware that hyperactive rs5522 receptors are trapping the fuel right at the valve, leaving the engine completely starved of energy.
Standard lab tests are clinically obsolete for this framework, as they can never detect actual intracellular tissue-level cortisol availability in people carrying the overactive rs5522 variant.
The roadmap to recovery doesn't require expensive, futuristic gene therapies. It requires utilizing low-cost, readily available, decades-old medications (like low-dose mineralocorticoid receptor antagonists) to plug the leak, stop the cortisol steal, and finally get fuel back to the GR.
Question: If my cells are starving for cortisol, why doesn't my brain detect it and make more?
Answer: The brain's feedback loop only monitors circulating hormone levels floating in the bloodstream. It cannot see what is happening inside individual cells.
This is not a radical or unproven concept in medicine. Mainstream clinicians already recognize that vital hormones—like insulin and thyroid—can look perfectly plentiful in a standard blood draw while failing to reach the cells due to cellular resistance. A similar roadblock happens here.
When you carry the rs5522 variant, your adrenal glands produce a normal amount of circulating cortisol, which keeps your standard blood, saliva, and urine panels looking deceptively healthy. But the moment that cortisol enters the tissue, an overactive mineralocorticoid receptor acts as a vacuum that hoards the supply, leaving your cells entirely starved of energy.The HPA axis cannot feel or detect this intracellular effect. Our HPA axis was evolutionarily designed for our ancestors to manage short-term surges of acute survival stress—like fleeing a predator—not to monitor chronic tissue starvation inside a single cell. Assuming that circulating hormone levels can accurately detect internal cellular processes is an outdated, 20th-century paradigm that completely misses the biology of tissue-level deficiency and resistance.
Emerging research confirms that Long COVID directly compounds this trap by inducing a severe form of Glucocorticoid Receptor (GR) resistance. A landmark 2026 cross-sectional study ("Glucocorticoid Resistance in COVID-19: Endocrine–Inflammatory Associations") documented that the SARS-CoV-2 virus induces profound immune dysregulation that significantly depletes and downregulates functioning GR-alpha receptors.
This creates a devastating double-whammy inside the cell:
The Baseline Vacuum: Your overactive MR is already relentlessly hoarding the cortisol needed to create cellular energy (ATP) and control inflammation.
The Viral Wreckage: The little bit of cortisol that manages to escape the vacuum hits GR receptors that have been structurally damaged and depleted by the virus.
Long covid happens when an inherited baseline deficiency gets permanently compounded by acquired viral damage, leaving the cell completely locked out from its energy pipeline. Even if only small viral fragments remain trapped in the tissues, they can drive chronic illness not by triggering full-blown viral symptoms, but by directly altering the shape and function of the glucocorticoid receptor inside the cell.
The only time your brain registers this localized deficiency is during brief, rare windows of extreme inflammatory crisis. If tissue starvation triggers an overwhelming spike of inflammatory signals, it can force a temporary, emergency surge of HPA axis activity. This is why you may have had high cortisol labs at one point. However, this is just a short-lived alarm response. Once the surge clears, the internal vacuum simply hoards the extra hormone, driving the cell straight back into its hidden shutdown.
Question: What if starting Spironolactone made me feel tired or weak?
Answer: Doses must be kept low (12.5-25mg). High doses can negatively impact electrolytes and trigger severe autonomic side effects.
It is important to note that dermatological doses used to treat acne are often higher. At elevated levels, spironolactone can aggressively suppress hormones and lower blood pressure, which may cause systemic fatigue, weakness, and brain fog in sensitive patient cohorts. This high-dose strain can completely mask the cellular benefits seen at lower thresholds.
For the framework, doses should remain strictly low. Additionally, if even a low dose of a mineralocorticoid receptor antagonist makes you more tired, it may indicate that your tissues require a baseline, external physiological level of cortisol to prevent your system from collapsing. In a body managing a continuous genetic capillary leak (rs5522), your adrenal glands are forced to run on high alert, producing constant cortisol to squeeze leaky blood vessels shut and keep your baseline blood pressure from crashing. In these cases, clinicians may opt to trial a standard physiological replacement dose of cortisol to stabilize your system before introducing the molecular shield.
Question: What is my doctor won’t prescribe an MR antagonist?
Answer: If your doctor isn't open to considering a low dose of a safe medication that has been around for decades, it might be worth looking for another doctor.
If your condition is not listed below, you may still benefit from an MR antagonist like Spironolactone, Elperenone or Finereone. Your clinical should consider prescribing a low dose to reset the cortisol imbalance between your receptors. While routine blood checks are a normal part of starting any new protocol, clinical studies show that at these ultra-low doses, potassium levels remain perfectly steady and safe for individuals with healthy kidneys.